Log in Free sign up

Motus GI (MOTS) News and press releases

News

From Benzinga Pro

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

88 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw Companies.

12 Health Care Stocks Moving In Wednesday's After-Market Session

Read Why Motus GI Stock Is Surging During Wednesday Premarket

Biotech, News, Penny Stocks, Health Care, Movers, Trading Ideas, General

Motus GI Holdings Inc (NASDAQ: MOTS) announced

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

21 Stocks Moving in Wednesday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Gainers The Singing Machine Company, Inc. (NASDAQ: MICS) shares rose 47.3% to $4.05 in pre-market trading.

12 Health Care Stocks Moving In Tuesday's After-Market Session

Motus GI Announces Topline Data From EU Study Of The Pure-Vu System In Hard-To-Prepare Patients Presented At Digestive Disease Week 2022

Biotech, General

The Pure-Vu system improved the adequate cleansing rate more than 200% to 97.7% in patients with a history of poor bowel preparation FORT LAUDERDALE, Fla., May 24, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc.,

HC Wainwright & Co. Maintains Buy Rating for Motus GI Hldgs: Here's What You Need To Know

Analyst Ratings

HC Wainwright & Co. has decided to maintain its Buy rating of Motus GI Hldgs (NASDAQ:MOTS) and lower its price target from $2.00 to $1.50. Shares of Motus GI Hldgs are trading up 2.97% over the last 24 hours, at $0.27 per share.

HC Wainwright & Co. Maintains Buy on Motus GI Hldgs, Lowers Price Target to $1.5

News, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Yi Chen maintains Motus GI Hldgs (NASDAQ:MOTS) with a Buy and lowers the price target from $2 to $1.5.

Motus GI Hldgs Q1 EPS $(0.09) Beats $(0.11) Estimate, Sales $20.00K Miss $80.00K Estimate

Motus GI Hldgs (NASDAQ:MOTS) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 18.18 percent increase over losses of $(0.11) per share from

Earnings Scheduled For May 12, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • Chicago Atlantic Real (NASDAQ:REFI) is projected to report earnings for its first quarter.

90 Biggest Movers From Yesterday

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Pre-Market Outlook, Markets, Movers

Motus GI Completes Enrollment iI European Union Feasibility Study Of Pure-Vu System As A New Method For Bowel Cleansing In Patients With A History Of Poor Bowel Preparation

Biotech, News, FDA, General

Topline data expected to be presented at a scientific conference in May 2022 Independent data shows ~5.4M outpatient colonoscopies are performed in EU annually1 New study data expected to

Motus GI Hldgs's Return On Capital Employed Overview

According to data from Benzinga Pro, during Q4, Motus GI Hldgs's (NASDAQ:MOTS) reported sales totaled $99.00 thousand. Despite a 0.12% increase in earnings, the company posted a loss of $4.82 million.

Motus GI Hldgs Q4 EPS $(0.10), Inline, Sales $99.00K Miss $140.00K Estimate

Motus GI Hldgs (NASDAQ:MOTS) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 16.67 percent increase over losses of $(0.12) per share from the same period last year. The

Earnings Scheduled For March 29, 2022

Earnings, News, Pre-Market Outlook, Markets

Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.

Earnings Preview: Motus GI Hldgs

Motus GI Hldgs (NASDAQ:MOTS) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that Motus GI Hldgs will report an earnings per share (EPS) of $-0.10.

30 Stocks Moving in Tuesday's Pre-Market Session

News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas

Press releases

From Benzinga Pro

Thinking about buying stock in Geovax Labs, Genocea Biosciences, Motus GI, Express, or Caleres?

Small Cap, Opinion, Press Releases

NEW YORK, May 25, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GOVX, GNCA, MOTS, EXPR, and CAL.

Motus GI Announces Positive Topline Data From EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022

Health Care, Press Releases, General

– The Pure-Vu system improved the adequate cleansing rate more than 200% to 97.7% in patients with a history of poor bowel preparation FORT LAUDERDALE, Fla., May 24, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc.,

Motus GI Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Earnings, Press Releases

Received FDA clearance in February 2022 to market Pure-Vu EVS, an all new, next-generation system that has been deployed to multiple hospitals in the first few weeks since launch Doubled the size of the sales team since

Motus GI to Release Fourth Quarter and Full Year 2021 Results and Provide a Business Update on March 29

News, Press Releases

FORT LAUDERDALE, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve

Motus GI to Participate in Two Upcoming Investor Conferences in March 2022

News, Press Releases

FORT LAUDERDALE, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ:MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes